Oncothyreon Inc (ONTY)

1.11
0.03 2.63
NASDAQ : Health Care
Prev Close 1.14
Open 1.15
Day Low/High 1.11 / 1.17
52 Wk Low/High 0.82 / 3.89
Volume 352.56K
Avg Volume 1.03M
Exchange NASDAQ
Shares Outstanding 94.96M
Market Cap 114.90M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oncothyreon Presents Phase 1b Results Of ONT-380 In Combination With T-DM1 In HER2+ Metastatic Breast Cancer At ASCO

Oncothyreon Presents Phase 1b Results Of ONT-380 In Combination With T-DM1 In HER2+ Metastatic Breast Cancer At ASCO

Encouraging results in ONT-380 combination therapy in patients with and without brain metastases

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stock look poised to break out and trade higher from current levels.

8 Stocks Under $10 Making Big Moves Higher

8 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Short Interest Increases 28.8% For ONTY

Short Interest Increases 28.8% For ONTY

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 1,604,331 share increase in total short interest for Oncothyreon Inc , to 7,172,405, an increase of 28.81% since 12/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. As Interim CEO And Expands Board With Additions Of Mark Lampert And Gwen Fyfe, M.D.

Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. As Interim CEO And Expands Board With Additions Of Mark Lampert And Gwen Fyfe, M.D.

-- Robert L. Kirkman, M.D. to Retire as Director, President and CEO --

Oncothyreon Stock Sees Short Interest Decrease By 14.2%

Oncothyreon Stock Sees Short Interest Decrease By 14.2%

The most recent short interest data has been released by the NASDAQ for the 11/30/2015 settlement date, which shows a 846,004 share decrease in total short interest for Oncothyreon Inc , to 5,133,307, a decrease of 14.15% since 11/13/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Oncothyreon Announces Data For ONT-380 In HER2-Positive Breast Cancer Patients With And Without Brain Metastases At The San Antonio Breast Cancer Symposium

Oncothyreon Announces Data For ONT-380 In HER2-Positive Breast Cancer Patients With And Without Brain Metastases At The San Antonio Breast Cancer Symposium

Company to Hold Conference Call to Discuss ONT-380 Data and Further Development Plans Today at 4:30 EST

Oncothyreon Announces Webcast To Review Updated Clinical Data On ONT-380 In HER2-Positive Breast Cancer Patients

Oncothyreon Announces Webcast To Review Updated Clinical Data On ONT-380 In HER2-Positive Breast Cancer Patients

Data to be Presented at San Antonio Breast Cancer Symposium

Interesting ONTY Put And Call Options For January 2016

Interesting ONTY Put And Call Options For January 2016

Investors in Oncothyreon Inc saw new options begin trading this week, for the January 2016 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONTY options chain for the new January 2016 contracts and identified one put and one call contract of particular interest.

Oncothyreon Reports Third Quarter 2015 Financial Results

Oncothyreon Reports Third Quarter 2015 Financial Results

Company to Hold Conference Call at 4:30 p.m. EST Today

First Week of ONTY December 18th Options Trading

First Week of ONTY December 18th Options Trading

Investors in Oncothyreon Inc saw new options become available this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONTY options chain for the new December 18th contracts and identified the following call contract of particular interest.

4 Stocks Under $10 to Trade for Big Breakouts

4 Stocks Under $10 to Trade for Big Breakouts

These stocks under $10 are within range of triggering breakout trades.

ONTY: Insiders vs. Shorts

ONTY: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 07/31/2015 settlement date, and Oncothyreon Inc is one of the most shorted stocks of the Russell 3000, based on 7.49 "days to cover" versus the median component at 5.46. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Oncothyreon Reports Second Quarter 2015 Financial Results

Oncothyreon Reports Second Quarter 2015 Financial Results

Company to Hold Conference Call at 4:30 p.m. EDT Today

Interesting ONTY Put And Call Options For February 2016

Interesting ONTY Put And Call Options For February 2016

Investors in Oncothyreon Inc saw new options become available this week, for the February 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Top-Performing Biotech and Drug Stocks During ASCO '15

Top-Performing Biotech and Drug Stocks During ASCO '15

Between May 12 and June 3, Oncothyreon's stock price rose 183%, best among all the companies presenting cancer drug research at the American Society of Clinical Oncology annual meeting.

Oncothyreon (ONTY) Stock Spikes Following Presentation on Breast Cancer Treatment Candidate

Oncothyreon (ONTY) Stock Spikes Following Presentation on Breast Cancer Treatment Candidate

Oncothyreon (ONTY) shares are up double digits after the company made a presentation for its metastatic breast cancer treatment candidate that showed positive results.

June 1 Premarket Briefing: 10 Things You Should Know

June 1 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are rising as investors look to personal income and manufacturing data at the start of a new trading month.